New members on UCB's Board of Directors

Brussels (Belgium), 22 March 2012 – 6.30 PM (CET) - regulated information - UCB today announces Harriet Edelman and Charles-Antoine Janssen as candidates to be appointed as new members of UCB's Board of Directors at UCB’s next General Assembly.

By the next General Assembly on April 26, 2012, the mandates of Karel Boone, Thomas Leysen and Gaëtan van de Werve will come to an end. Alexandre Van Damme has notified his resignation. Roch Doliveux, CEO of UCB, said: "Karel Boone, Thomas Leysen, Alexandre Van Damme and Gaëtan van de Werve have served very successfully as UCB Board members and we would like to thank them for their key contribution and healthy challenges. Special tribute and thanks go to Karel Boone, our Chairman who has reached the statutory age limit. Karel has thoughtfully stimulated and supported UCB's transformation since 2000". Gerhard Mayr who is to succeed Karel Boone as Chairman of the Board of Directors of UCB said : "we are delighted to have Harriet and Charles-Antoine as new candidates. Both bring unique experience and views to the Board, enabling us to continue our journey as a patient-centric biopharma leader."

Harriet Edelman is currently Vice Chairman of Emigrant Bank, the largest privately held bank in the United States. She has responsibility for Finance Operations and Information Technology for New York Private Bank & Trust and its operating bank, Emigrant Bank. Harriet has been with the bank since 2008 and, prior to that, was employed at Avon Products, Inc., a leading global beauty company with over $10 billion in annual revenue. Harriet held a number of leadership roles at Avon Products throughout her career, including Senior Vice President & Chief Information Officer, Senior Vice President, Global Supply Chain and numerous prior executive positions in Marketing, Sales and Customer Service. Harriet serves as a director of Brinker International, Inc., an owner, operator and franchisor of restaurants, and Ariba, Inc., a provider of supply chain procurement and spend management solutions. She also serves on the Board of Trustees of Bucknell University and the New York Blood Center. Harriet holds a Bachelor degree from Bucknell University and a Master of Business Administration from Fordham University.

Charles-Antoine joined UCB in 2001 where he held several management positions at global and local levels. Among other responsibilities he was head of Business Development, General Manager of Austria and India, and most recently managed International Major Markets Operations. Prior to UCB, Charles-Antoine worked for Merrill Lynch in London from 1996-2000 where he was Vice-President Equities Research then Vice-President New Derivatives Europe. He holds a Bachelor of Laws degree from Brussels University (ULB) and an AMP from Harvard Business School. Today Charles-Antoine Janssen teaches social entrepreneurship and sustainable development at the Solvay Brussels School of Management and Economics, Brussels University (ULB). Over the years, Charles-Antoine has volunteered with several non-profit organisations and launched various societal wealth creation initiatives.

Both candidates as Board members have been selected with a view to further broaden the skills of the Board and to align it with the changing and demanding environment. Subject to the approval of the proposed resolutions by the General Assembly, the new Board would include seven Independent Board members namely: Bert De Graeve, Harriet Edelman, Peter Fellner, Jean-Pierre Kinet, Tom McKillop, Gerhard Mayr (Chairman), and Norman Ornstein. Five other members of the Board would not be independent : Evelyn du Monceau (Vice Chair) Roch Doliveux (Executive Director), Charles-Antoine Janssen, Arnoud de Pret and Bridget van Rijckevorsel.

For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com

France Nivelle, Global Communications, UCB
T +32 2 559 9178, france.nivelle@ucb.com

Laurent Schots, Media Relations, UCB
T +32.2.559.9264, laurent.schots@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.